Antisoma, a biotechnology company specializing in the development of novel drugs for the treatment of cancer, released a statement that the vaccine ASA404 improves anticancer responses and survival for patients with non-small cell lung cancer.
ASA404 is known as a vascular disrupting agent (VDA). ASA404 is different from angiogenenesis inhibitors that disrupt the new formation of blood vessels. This vaccine disrupts established blood vessels that feed cancer cells.
The researchers concluded that ASA404 appears promising in the treatment of advanced non-small cell lung cancer. A Phase III clinical trial is expected to begin in 2008. This is the last step prior to FDA review.
Antisoma, a cancer drug developer in London, England, and EcoBiotics, harnessing nature's chemistry for
contemporary drug discovery in Queensland, Australia, have entered into an agreement to study 
